MedTrace Logo

Pre-Prostatectomy Lovastatin on Prostate Cancer

NCT01478828 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2019-03-27

Study results available
· View outcomes & findings →

Summary

To determine the dose of continuous daily oral lovastatin needed to achieve MYC \[v-myc myelocytomatosis viral oncogene homolog (avian)\] down-regulation in prostatectomy specimens in intermediate-/high-risk localized prostate cancer patients.

Conditions

Interventions

DRUG

Lovastatin

oral qd varying dose escalations/de-escalations

Sponsors & Collaborators

  • Patrick C Walsh Prostate Cancer Research Fund

    collaborator UNKNOWN

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    lead OTHER

Principal Investigators

  • Phouc Tran, M.D. · Johns Hopkins University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-13
Primary Completion
2013-04-08
Completion
2013-04-08

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01478828 on ClinicalTrials.gov